All In Biotech

Drug Trial Radar · NCT01302054

A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).

Last checked: Nov 20, 2026Latest source record: Dec 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 990 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

990

Actual

Start

May 2011

Primary completion

May 2012

Study completion May 2012

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with overactive bladder are often treated with tolterodine, a medication that helps relax the bladder, helping symptoms of urinary incontinence and urinary frequency. Sometimes patients do not have a satisfactory response, and may benefit from trying an alternative oral medicine. Fesoterodine is related to tolterodine by producing the same active substance that acts on the bladder, but potentially at higher and more effective levels. So, a patient who has a poor response to tolterodine may still obtain a good response to fesoterodine. This study will help find out if this is what happens.

Conditions

  • Urinary Bladder, Overactive

Interventions

  • Fesoterodine 8 mgDrug

    Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.

  • PlaceboDrug

    Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 HoursTime frame: Baseline, Week 12
  2. Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12Time frame: Baseline, Week 12

Locations

176 sites in 15 countries. Site status is shown where the registry gives one.

  • Radiant Research, Inc.

    Birmingham, Alabama

  • Alabama Internal Medicine, PC

    Birmingham, Alabama

  • Brown and McCool Gynecology

    Fairhope, Alabama

  • Radiant Research, Inc.

    Chandler, Arizona

  • Eclipse Clinical Research

    Green Valley, Arizona

  • Radiant Research, Inc.

    Tucson, Arizona

  • Urological Associates of Southern Arizona, PC

    Tucson, Arizona

  • American Institute of Research

    Los Angeles, California

  • Moaz Khorsandi, DO

    Los Angeles, California

  • Urology Group of Southern California

    Los Angeles, California

  • Institute for Advanced Urology

    Los Angeles, California

  • Center for Clinical Trials, LLC

    Paramount, California

  • Sierra Clinical Research

    Roseville, California

  • Superior Research LLC

    Sacramento, California

  • California Research Foundation

    San Diego, California

  • Medical Center for Clinical Research

    San Diego, California

  • Advanced Urology, PC

    Parker, Colorado

  • Thameside Obstetrics/Gynecological Center

    Groton, Connecticut

  • S.H.E. Medical Associates

    Hartford, Connecticut

  • Chase Medical Research, LLC

    Waterbury, Connecticut

  • Manatee Medical Research Institute, LLC

    Bradenton, Florida

  • Atlantic Institute of Clinical Research

    Daytona Beach, Florida

  • SJS Clinical Research

    Destin, Florida

  • Ocala Urology Specialists

    Ocala, Florida

  • Renstar Medical Research, Inc.

    Ocala, Florida

  • Accord Clinical Research, LLC

    Port Orange, Florida

  • Pinellas Urology, Inc.

    St. Petersburg, Florida

  • Florida Urology Partners

    Tampa, Florida

  • The Office of Georgis Patsias, MD, PA

    Wellington, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • Atlanta Medical Research Institute, LLC

    Alpharetta, Georgia

  • Radiant Research, Inc.

    Atlanta, Georgia

  • In-Quest Medical Research, LLC

    Duluth, Georgia

  • Prism Research Group

    Rome, Georgia

  • Valley Health Care

    Rome, Georgia

  • Fox Valley Clinical Research Center, LLC

    Aurora, Illinois

  • Radiant Research, Inc.

    Chicago, Illinois

  • Urology of Indiana, LLC

    Noblesville, Indiana

  • Radiant Research, Inc.

    Overland Park, Kansas

  • Regional Urology, LLC

    Shreveport, Louisiana

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.